Sanofi: 13F holdings
CIK 11214042026Q2
| Positions | 10 |
|---|
| Reported value | $534.0m |
|---|
| Filed | 2026-07-28 |
|---|
Change since last quarter
| Positions | 10 (+1 vs prior quarter) |
|---|
| Reported value | $534.0m (+59.0%) |
|---|
Top 10 holdings
| Security | Shares | Value | Weight |
|---|
| MeiraGTx Holdings plc | 12,197,737 | $164.8m | 30.9% |
| INBX Inhibrx Biosciences, Inc. | 1,157,926 | $109.7m | 20.5% |
| NVAX Novavax | 6,880,481 | $64.8m | 12.1% |
| ANAB AnaptysBio | 821,917 | $55.5m | 10.4% |
| Odyssey Therapeutics Inc. | 1,991,918 | $37.3m | 7.0% |
| Agomab Therapeutics NV | 2,783,096 | $36.1m | 6.8% |
| MapLight Therapeutics Inc. | 912,041 | $32.7m | 6.1% |
| First Tracks Biotherapeutics Inc. | 821,917 | $16.5m | 3.1% |
| IMRX Immuneering Corp | 2,708,559 | $13.5m | 2.5% |
| Q32 Bio Inc. | 244,083 | $3.1m | 0.6% |
Get the full book
import finzdata as yf
yf.Client().manager_holdings(cik="1121404")
Every position, quarter by quarter since 2013, with adds, trims and exits, on the look-back bundles.
Get a free API keySee history bundlesDownload free samples